Skip to content

Metagenomi Therapeutics, Inc.

MGX

CIK 0001785279

← back to feed
Revenue (TTM)
$22.55M
−51.8% YoY Q1 May 2026
Net Income (TTM)
−$88.4M
−12.6% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.38
0.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-426.8%
Q1 May 2026
Net Margin
-392.1%
Q1 May 2026
Free Cash Flow (TTM)
−$98.76M
Q1 May 2026
Cash
$25.31M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
37.65M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings